Nichole Tucker

In an interview with Targeted Oncology, Muhammad Siddiqui, MD, explained the role that palliative medicine plays in a cancer treatment plan and how oncologists and palliative care physicians can work together in patients’ best interests.

In an interview with Targeted Oncology™, Michelle M. Issac, MD, discussed the goals of both palliative care and oncology care professionals as they support patients with cancer.

In an interview with Targeted Oncology, Penn Medicine’s Qian Wang, MD, MPH, gives an in-depth overview of the molecular targets in the small cell lung cancer field.

Activation of the JAK/STAT pathway with ruxolitinib may be a future option for patients with newly diagnosed, high-grade glioma.

In an interview with Targeted Oncology, Rachna T. Shroff, MD, MS, FASCO, discussed new systemic therapies that are available or being developed to treat patients with intrahepatic cholangiocarcinoma.

In an interview with Targeted Oncology during the International Liver Cancer Association Annual Conference 2023, Tim F. Greten, MD, discussed the key highlights from his presentation on tissue biopsy, and his thoughts on the opposing argument in favor of liquid biopsy.

Results from the phase 1 EQUILIBRIUM study signal better outcomes for patients with newly diagnosed, MGMT methylated glioblastoma.

CLN-619 has emerged for the treatment of advanced solid tumors in the clinical trial setting. Early results are promising, says lead investigator Judy Wang, MD

Positive findings from CheckMate-76K have led the FDA to approve adjuvant nivolumab monotherapy for the treatment of patients with completely resected stage IIB or IIC melanoma.

In the first comprehensive study of patients with pancreatic cancer treated with either MRI-guided radiotherapy or CT-guided radiotherapy, experts state MRI-guided treatment may be safer.

Further development of 177Lu-satoreotide tetraxetan is expected after promising data from a phase 1/2 trial were recently published.

The final analysis of the phase 2 ASPEN-06 is underway and expected to complete in 2024.

Priority review to the biologics license application for odronextamab has been granted by the FDA for adult patients with follicular lymphoma and diffuse large B-cell lymphoma.

Topline results from MARIPOSA reveal a survival advantage with amivantamab plus lazertinib vs osimertinib in patients with EGFR-mutant non–small cell lung cancer. Additional follow-up is planned.

Bosutinib has a new indication in leukemia as a well as a newly-approved formulation.

In an interview with Targeted Oncology, Richard S. Finn, MD, discussed his ILCA Annual Conference 2023 presentation on optimal frontline treatment in hepatocellular carcinoma and how this standard of care could evolve in the future.

ABM-1310 is an investigational small molecule BRAF inhibitor that is being development for the treatment of various BRAF V600E-mutant solid tumors.

The investigational antibody-drug conjugate, MYTX-011, is one step further in development for the treatment of non–small cel lung cancer with cMET overexpression.

Results from the phase 3 NETTER-2 study will be presented at an upcoming medical conference and shared with drug regulators.

Following positive phase 1 results, HPN328 treatment in now under evaluation in a phase 1/2 trial.

A phase 2 study, PUMA-ALI-4201, will further investigate alisertib for the treatment of small cell lung cancer.

A new treatment geared to treat the most common driver of RAS-addicted solid tumors has been dosed for the first time in humans.

Seagen Inc., and Astellas Pharma Inc., report that both primary end points of the phase 3 EV-302 clinical trial have been met.

The phase 3 LEAP-006 study of pembrolizumab plus lenvatinib and chemotherapy has missed its dual primary end points.

The FDA has granted fast track designation to MWTX-003 for the treatment of patients with polycythemia vera.

The investigational PLK1 inhibitor, CYC140, is the focus of important clinical research in advanced solid tumors, leukemias, and lymphomas.

In an interview with Targeted Oncology, Eirwen M. Miller, MD, discussed the endometrial cancer landscape and future projections.

A speedy review of an approval application for belzutifan has been undertaken by the FDA.

A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.

Momelotinib has emerged as a new FDA-approved treatment option for patients with myelofibrosis and anemia.